Antibody
Discovery
Start your project
From Immunization to lead selection Smarter, faster and
de-risked
We specialize in high-performance antibody generation powered by the Beacon® platform, enabling rapid isolation and functional screening of top-quality antibodies within days. Our versatile immunization strategies (protein, peptide, cell, or mRNA-based) fit every target challenge.
From early discovery to lead selection, MImAbs de-risks your development and streamlines your path toward clinical candidates.
Solving the Key Challenges of Ab Discovery
Rapid & Reliable Discovery
Identify new antibodies based on target binding, affinity, cross reactivity and functionality, all on Day1 using our Beacon® platform.
Tailored Immunization Strategies
Protein, peptide, cell, or RNA-based approaches adapted to your target complexity.
De-risked Development
Expert guidance and real-time functional screening ensure robust, validated leads.
High-Performance Antibody Generation for Discovery without Delay
Proven Discovery Expertise
Hundreds of high-quality antibodies generated using the Beacon® platform, against various target types.
Speed and Efficiency
From customized immunization strategies to lead selection within days, enabling very fas timelines.
Integrated Functional Screening
Real-time assessment of antibody binding and cross-reactivity ensures rapid identification of the best leads based on function.
- RNA: Ideal for targeting native membrane proteins and complex conformational epitopes that are difficult to produce in vitro (proprietary protocol)
- Peptide: Suitable for producing antibodies against defined linear epitopes or to target epitopes arising from post-translational modifications
- Protein: Best for generating antibodies against soluble proteins or containing a large extracellular domain
- Cells: Useful when the antigen is difficult to produce as protein, frequently combined with RNA immunization
- Classical: Delivers broad and strong antibody responses for projects requiring diverse and high-affinity antibodies.
- RIMMS (Repetitive Immunization Multiple Sites): Fast, streamlined antibody production delivering target responses in two weeks.
Beacon technology:
- Use case: Rapid, high-throughput cloning and screening of single antibody-secreting cells directly obtained from immunized animals or human donors
- Properties: Real-time functional assays at the single-cell level, with high-precision multiplex screening of antibodies on cells transfected with the target antigen or antigen-coated beads. Allowing the direct measure of binding affinity, internalization, cross reaction or blocking activity
- Strenght: Speed, precision, multiplexing capability
- Use case: Traditional monoclonal antibody production by fusion of B cells from an immunized animal with myeloma cells to generate stable antibody-producing clones.
- Properties: Proven, reliable but slow and low throughput method with well-established protocols
- Strenght: cost-effectiveness
- Use case: in vitro selection of antibodies from libraries of recombinant M13 phages carrying antibody genes from human donors, non-immune or immunized animals.
- Properties: Large size libraries (>10^9); may avoid animal immunization; better for challenging antigens, allows human antibody discovery.
- Strenght: Fast and cost-effective
- Sequence annotation and clustering
- Comparative analysis
- Clonal lineage tracing.
Single B cell screening
In a single-day experiment, the Bruker Beacon® platform is used to identify and isolate individual plasma cells producing antibodies against a tumor-associated antigen (TAA). The platform enabled high-throughput screening for neutralizing activity and cross-reactivity against antigen analogs, delivering a diverse panel of candidate antibodies in a single run.
